Symantha Melemed

Symantha Melemed, PhD, currently serves as the Senior Vice President and Head of Immuno-Oncology at Astellas Pharma, a position held since August 2024. Previously, Melemed held senior leadership roles at G1 Therapeutics, Inc., including Senior Vice President of Development and Vice President of Clinical Development from April 2022 to August 2024. During tenure at AbbVie from June 2020 to April 2022, Melemed was the Global Asset Strategy Leader for Oncology. Earlier experience at Eli Lilly and Company spanned from 2006 to 2020, with roles such as Global Product Team Leader for Oncology, Senior Director of Oncology Tailoring, and Clinical Research Scientist, specializing in global clinical drug development and patient tailoring in oncology. Educational background includes a PhD in Molecular Genetics from Iowa State University and an NIH Fellowship focusing on Cancer Genetics/Cell Signaling from the Indiana University School of Medicine.